Depomed, Inc. Announces Strong Positive Phase II Trial Results For Once Daily Gabapentin GR(TM) To Treat Symptoms Of Diabetic Peripheral Neuropathy

MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (Nasdaq:DEPO) today announced statistically significant efficacy benefits of its Gabapentin GR™ extended release tablets for the once daily treatment of pain in patients with diabetic peripheral neuropathy (DPN), a nerve disorder caused by diabetes.